title: To what extent will 5-aminolevulinic acid change the face of malignant glioma surgery?
abstract: Glioma surgery is an essential part of glioma management; however, fully achieving the goal of surgery has been uncommon. The goal of surgery is 'maximal safe resection' with the accepted target for maximal being complete resection of the contrast-enhancing tumor. This ideal result was obtained in less than 30% of cases in centers of excellence until a few years ago. The development of fluorescence-guided surgery using 5-aminolevulinic acid has initiated a radical change. Over the past 5 years, various groups have published rates of complete resection of the enhancing tumor that exceed 80%. In the coming years, as the use of the technology expands, complete resection should become a common, predictable result at many centers. Consequently, adjuvant therapies that benefit from resection could play a bigger role, resection could be incorporated as a variable in randomized trials and distant recurrence might become a more common problem.
authors.affiliation: Department of Neurosurgery, Clínica Universidad de Navarra, Navarre, Spain.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Díez Valle
authors.affiliation: Department of Neurosurgery, Clínica Universidad de Navarra, Navarre, Spain.
authors.forename: Sonia
authors.initials: S
authors.lastname: Tejada Solis
mesh_terms: D000622:Aminolevulinic Acid; D001932:Brain Neoplasms / Q000601:surgery*; D017326:Clinical Trials, Phase III as Topic; D005910:Glioma / Q000601:surgery*; D006801:Humans; D019635:Neurosurgical Procedures / Q000379:methods*; D061848:Optical Imaging / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D025321:Surgery, Computer-Assisted / Q000379:methods*
chemical_list: D000622:Aminolevulinic Acid
keywords: 5-aminolevulinic acid; fluorescence-guided surgery; glioblastoma; malignant glioma; surgery